ArticleLeukemia research reports2016

Clonal evolution of AML on novel FMS-like tyrosine kinase-3 (FLT3) inhibitor therapy with evolving actionable targets.

Pashtoon M Kasi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.